Santarus — Investor Presentation (July 2013)
32 slides from Santarus's investor presentation, Jul 9, 2013
Slide 1: NasdaqGS: SNTS July 9, 2013
NasdaqGS: SNTS July 9, 2013
Slide 2: Safe Harbor
Safe Harbor This presentation may include forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its plans o
Slide 3: Investment Highlights
Investment Highlights Profitable specialty biopharmaceutical company with a focus on proprietary products Attractive mix of commercial and development opportunities February 2013 launch of Uceris(r) (budesonide) for induction of remission in patients with active, mild to moderate ulcerative colitis
Slide 4: Mix of Commercial & Development Opportunities
Mix of Commercial & Development Opportunities 4 Focus on proprietary products for physician specialists Balancing investments in R&D and SG&A to achieve meaningful, sustainable growth in revenues and profits Sales potential of ~$650M - $750M* Gastroenterology Uceris(r) Zegerid(r) Type 2 diabetes Glu
Slide 5: Specialty Focus - Leverage Commercial Investment
Specialty Focus - Leverage Commercial Investment 5 Near term 2013 Medium term Long term Endocrinologists & Selected PCPs (150 reps) Glumetza(r), Cycloset(r), Fenoglide(r) Rheumatologists (30 reps) SAN-300 Gastroenterologists (85 reps) Uceris(r) , Zegerid(r) Rifamycin SV MMX, SAN-300 Allergists/ Immu
Slide 6: Financial Strategy - Increase Shareholder Value
Financial Strategy - Increase Shareholder Value 6 Leverage sales organization Increase sales per rep Increase revenue Decrease SG&A as % of revenue Maintain R&D as % of revenue Increase profits & cash flow Invest for future growth
Slide 7: Growth Strategies
Growth Strategies Maximize value of existing portfolio through additional formulations or indications Continue to seek new marketed or late-stage development products through license or acquisition, including company acquisitions Gastroenterology Endocrinology Other selected specialties Plan to add
Slide 8: Sales Force Product Mix
Sales Force Product Mix 8 235 Sales Reps Primary Care Physicians Endocrinologists Glumetza(r) Glumetza Cycloset(r) Cycloset Fenoglide(r)/ Zegerid* Fenoglide Gastroenterologists Uceris(r) Zegerid(r) * Fenoglide/Zegerid to select primary care physicians based on prescribing patterns
Slide 9: Uceris
Uceris(r)* 9 FDA approved on January 14, 2013 for induction of remission in patients with active, mild to moderate ulcerative colitis Commercial launch commenced mid-February, 2013 $6.6 million net sales in 1Q 2013 Ulcerative colitis, an inflammatory bowel disease (IBD), affects approximately 700,00
Slide 10: Established Therapies for Mild to Moderate Ulcerative Colitis
Established Therapies for Mild to Moderate Ulcerative Colitis 10 Step-up according to severity at presentation or failure at prior step 5-ASA Systemic Corticosteroids Anti-TNF^ Disease severity at presentation 5-ASA / Thiopurine 5-ASA Anti-TNF^ Induction Maintenance Cyclosporine Thiopurine Severe Mo
Slide 11: Selected IBD Products - U.S. TRx and IMS Sales Trends - May 2013
Selected IBD Products - U.S. 11 TRx and IMS Sales Trends - May 2013 * Generic version of Entocort EC launched in June 2011 (CHART) (CHART)
Slide 12: Uceris Weekly Prescription and Prescriber Trends
Uceris(r) Weekly Prescription and Prescriber Trends 12 Source: IMS Health, Weekly NPA (CHART)
Slide 13: Zegerid
(CHART) Zegerid(r)* 13 Source: IMS Healthcare, Weekly NPA Par Pharmaceutical ceased generic distribution after appellate court ruling in favor of Santarus in Sept 2012, but has continued to challenge in lower court Jury trial to determine damages scheduled for November 2014 Patents expire in July 20
Slide 14: Glumetza
Glumetza(r)* 14 * Please see www.Glumetzaxr.com for full prescribing and safety information including a Black Box warning Source: IMS Health, Weekly NPA Once-daily, metformin extended-release oral tablet Controlled delivery may improve GI tolerability and allow more patients to reach A1C goal 18% TR
Slide 15: Glumetza Market Potential
Glumetza(r) Market Potential 15 (CHART) 0.4M
Slide 16: Cycloset
Cycloset(r)* 16 First and only centrally acting, oral type 2 diabetes product Recently added to AACE Comprehensive Diabetes Management Algorithm Unique formulation of bromocriptine Consistent A1C control Demonstrated cardiovascular safety profile with 52% relative risk reduction in MACE** in pivotal
Slide 17: Fenoglide
(CHART) Fenoglide(r)* High cholesterol is a co- morbid condition frequently associated with type 2 diabetes Strong overlap with current called-on physicians Net sales of $1.9 million reported by Santarus in 1Q 2013 17 Indicated for the treatment of high cholesterol * Please see www.Fenoglide.com for
Slide 18: Santarus Development Pipeline
Santarus Development Pipeline Santarus Development Pipeline CONTRIBUTE study BLA under FDA review w/PDUFA in April 2014 SPA to be discussed with FDA Phase II timing TBD Anticipate pre-IND mtg w/FDA Anticipate pre-IND mtg w/FDA One Phase III study completed * *Santarus will share data from a second P
Slide 19: Ruconest (recombinant human C1 esterase inhibitor)
Ruconest met the primary endpoint in Phase III study conducted under Special Protocol Assessment Two prior placebo-controlled studies completed with statistically significant results Biologics License Application (BLA) under FDA review with PDUFA date of April 16, 2014 Plan to explore clinical and r
Slide 20: Ruconest - Positive Phase III Data
Ruconest(r) - Positive Phase III Data for 50 U/kg Study 1310 Results Study 1310 Results Study 1310 Results Study 1310 Results Intent-to-Treat Population (N=75) Ruconest 50 U/kg (n = 44) Placebo (n = 31) P-value Median time to the beginning of symptom relief (Primary Endpoint) (Based on Treatment Eff
Slide 21: U.S. HAE Treatments - Evolving to Acute Therapies
U.S. HAE Treatments - Evolving to Acute Therapies 21 Cinryze(r) 10-15% of patients Most severe cases Very frequent attacks History of life- threatening or intense pain Significant impact on QOL Berinert(r), Kalbitor(r), Firazyr(r) 60-70% of patients Mild/moderate cases More frequent attacks Peripher
Slide 22: Rifamycin SV MMX
Rifamycin SV MMX(r) Clinical activity in infectious diarrhea appears comparable to Xifaxan(r) (rifaximin) Positive top-line results in multicenter, randomized, double-blind Phase III clinical study for treatment of patients (n = 264) with travelers' diarrhea Median TLUS was 46.0 hours for rifamycin
Slide 23: SAN-300 (anti-VLA-1 antibody)
SAN-300 (anti-VLA-1 antibody) Humanized antibody created by Biogen Idec Efficacy in multiple preclinical models of inflammation, including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma and organ transplant Phase I clinical study (intravenous and subcutaneous formulations) compl
Slide 24: 1Q 2013 and Full Year 2012 Total Revenues
2013 2012 2012 Product sales, net Glumetza(r) $ 41.5 $ 31.2 $ 145.0 Zegerid(r) 24.6 8.5 48.0 Uceris(r) 6.6 - - Cycloset(r) 3.9 3.6 14.5 Fenoglide(r) 1.9 1.8 7.1 Total product sales, net 78.5 45.1 214.6 Other revenue 0.9 0.8 3.4 Total revenues $ 79.4 $ 45.9 $ 218.0 1Q 2013 and Full Year 2012 Total Re
Slide 25: 1Q 2013 and Full Year 2012 Financial Results
Three Months Ended March 31, Cash, cash equivalents & short-term investments of $97.6 million at March 31, 2013 1Q 2013 and Full Year 2012 Financial Results (Unaudited) 25 Year Ended Dec 31, ($ Millions) Except per share amounts 2013 2012 2012 Total revenues $ 79.4 $ 45.9 $ 218.0 Total costs & expen
Slide 26: 2010 - 2012 Financial Results and 2013 Estimates
(CHART) 2010 - 2012 Financial Results and 2013 Estimates 26 **Midpoint of Santarus internal 2013 financial outlook provided on May 6, 2013 * Adjusted earnings is a non-GAAP financial measure. A reconciliation of adjusted earnings to GAAP net income can be found at the end of this presentation. (CHAR
Slide 27: 2013 Completed and Potential Milestones
2013 Completed and Potential Milestones 27 FDA approval for Uceris(r) 1/14/13 Uceris commercial launch 2/14/13 Submit BLA for Ruconest(r) in HAE (April 2014 PDUFA) 4/16/13 Complete enrollment in Uceris Phase IIIb study Mid-2013 Initiate SAN-300 Phase IIa study in RA patients 4Q 2013 Initiate proof-o
Slide 28: Investment Highlights
Investment Highlights Profitable specialty biopharmaceutical company with a focus on proprietary products Attractive mix of commercial and development opportunities February 2013 launch of Uceris(r) (budesonide) for induction of remission in patients with active, mild to moderate ulcerative colitis
Slide 29: Additional Information
Additional Information
Slide 30: Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings - 1Q 2013 and 1Q 2012
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings (Unaudited) - 1Q 2013 and 1Q 2012 Earnings (Unaudited) - 1Q 2013 and 1Q 2012 Earnings (Unaudited) - 1Q 2013 and 1Q 2012 30 Adjusted earnings, is a non-GAAP financial measure. Santarus believes that the presentation of this non-GAAP fina
Slide 31: Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings 2010-2012
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings in 2010-2012 Financial Results (Unaudited) Earnings in 2010-2012 Financial Results (Unaudited) Earnings in 2010-2012 Financial Results (Unaudited) 31
Slide 32: Reconciliation of Non-GAAP Adjusted Earnings Guidance for 2013
Reconciliation of GAAP Net Income to Non-GAAP Adjusted Earnings Guidance for the Year Ending December 31, 2013 32 32 * Santarus internal 2013 financial outlook provided on May 6, 2013 2013 Financial Outlook for Net Income and Non-GAAP Adjusted Earnings* ($ Millions)